Komori
Earnings4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

In the first quarter, net sales increased 11.8% year on year and operating profit increased 16.8%, while ordinary profit and profit attributable to owners of the parent declined due to the drop in dividend income following the one-off increase recorded in the same period of the previous year. In addition, full-year forecasts were revised upward following a review of foreign exchange assumptions and strong performance in the Asia, Japan and Europe segments.

Worth reading
44Recurring
Scored from 5 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
2800
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAP
Net Sales91,624¥ millionYear on year +11.8%Progress 24.6%
Operating profit13,663¥ millionYear on year +16.8%Progress 30.4%
Ordinary income14,491¥ millionYear on year -10.1%Progress 30.6%
Net income attributable to owners of the parent10,650¥ millionYear on year -9.5%Progress 30.3%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥47.14
Financial position at period-end
Total assets487,151¥ million
of which net assets 328,459 ¥ millionEquity ratio 63.5%vs. prior year-end +1.4pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Segment revenueJapan ¥42,864 million (YoY +5.2%), Americas ¥5,465 million (YoY +8.3%), Europe ¥6,684 million (YoY +19.9%), Asia ¥35,604 million (YoY +19.7%)
Segment profitJapan ¥6,867 million (YoY +8.8%), Americas ¥226 million (YoY +22.6%), Europe ¥664 million (YoY +392.7%), Asia ¥5,676 million (YoY +18.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥372,300 million (YoY +8.3%)
Operating profit¥45,000 million (YoY +9.4%)
Ordinary income¥47,400 million (YoY -1.2%)
Net income¥35,200 million (YoY +2.8%)
Revision to Earnings ForecastNet Sales 369,500 / Operating profit 43,800 / Ordinary income 46,100 / Profit attributable to owners of the parent 34,500 → Net Sales 372,300 / Operating profit 45,000 / Ordinary income 47,400 / Profit attributable to owners of the parent 35,200(Net Sales 0.8 / Operating profit 2.7 / Ordinary income 2.8 / Profit attributable to owners of the parent 2)
Annual Dividend Forecast¥46 → ¥50
Factors Behind Changes in Business Performance

In Japan, skincare products such as eye-care products and Hada Labo performed well, while overseas, the Asia segment performed well, led by ユーヤンサン・インターナショナル社. Operating profit increased as the effect of higher sales exceeded the increase in selling, general and administrative expenses, while ordinary profit and profit attributable to owners of the parent declined due to the drop in one-off dividend income following the increase recorded in the same period of the previous year.

Disclosure regarding the going concern assumption

No applicable matters.

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew — companies / Excluded — companies / Company name Not disclosed
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥311 million / Extraordinary loss No applicable matters.
Depreciation and amortization¥3,950 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End236,178,310
Treasury Shares at Period-End10,214,018
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 June 2026
Net Sales¥91,624 million (YoY +11.8%)
Operating profit¥13,663 million (YoY +16.8%)
Ordinary income¥14,491 million (YoY -10.1%)
Profit attributable to owners of the parent¥10,650 million (YoY -9.5%)
Net income per share¥47.14
Equity ratioEnd of the current fiscal period 63.5 / End of previous period 62.1
Total assets¥487,151 million
Net assets¥328,459 million
Full-year earnings forecastNet Sales ¥372,300 million (YoY +8.3%) / Operating profit ¥45,000 million (YoY +9.4%) / Ordinary income ¥47,400 million (YoY -1.2%) / Net income ¥35,200 million (YoY +2.8%)
Revision to Earnings ForecastNet Sales 369,500 / Operating profit 43,800 / Ordinary income 46,100 / Profit attributable to owners of the parent 34,500 → Net Sales 372,300 / Operating profit 45,000 / Ordinary income 47,400 / Profit attributable to owners of the parent 35,200(Net Sales 0.8 / Operating profit 2.7 / Ordinary income 2.8 / Profit attributable to owners of the parent 2)
Annual Dividend Forecast¥46 → ¥50
Segment revenueJapan ¥42,864 million (YoY +5.2%), Americas ¥5,465 million (YoY +8.3%), Europe ¥6,684 million (YoY +19.9%), Asia ¥35,604 million (YoY +19.7%)
Segment profitJapan ¥6,867 million (YoY +8.8%), Americas ¥226 million (YoY +22.6%), Europe ¥664 million (YoY +392.7%), Asia ¥5,676 million (YoY +18.8%)
Depreciation and amortization¥3,950 million
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥311 million / Extraordinary loss No applicable matters.
Disclosure regarding the going concern assumptionNo applicable matters.
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew — companies / Excluded — companies / Company name Not disclosed
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End236,178,310
Treasury Shares at Period-End10,214,018
Factors Behind Changes in Business PerformanceIn Japan, skincare products such as eye-care products and Hada Labo performed well, while overseas, the Asia segment performed well, led by ユーヤンサン・インターナショナル社. Operating profit increased as the effect of higher sales exceeded the increase in selling, general and administrative expenses, while ordinary profit and profit attributable to owners of the parent declined due to the drop in one-off dividend income following the increase recorded in the same period of the previous year.
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Full-year forecasts were revised because the forecast exchange rate was revised from ¥155 to ¥158 per US dollar and the Chinese yuan assumption was revised from ¥22 to ¥23, in addition to the Asia, Japan and Europe segments performing better than expected during the cumulative first-quarter period. The decline in first-quarter ordinary profit and profit attributable to owners of the parent was attributed to the drop in one-off dividend income following the increase recorded in the same period of the previous year.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | ROHTO PHARMACEUTICAL CO.,LTD. (4527) timely disclosure | Komori